Linda Dwoskin, PhD, Chair, is the Endowed Professor in Pharmaceutical Education and Associate Dean for Research, College of Pharmacy. Dr. Dwoskin has over 23 years of experience in leading a continuously NIH-funded research program focused on neuropharmacology and drug discovery. Dr. Dwoskin is co-founder of a drug discovery company, Yaupon Therapeutics, Inc. and several drugs discovered in her laboratory are currently in clinical development.

Bradley D. Anderson, PhD, is the H.B. Kostenbauder Professor and Director, Drug Development Division in the College of Pharmacy. Dr. Anderson holds several patents in pro-drug design and drug formulation design.

Michael Bardo, PhD, Professor of Psychology, College of Arts and Sciences, is Director of the NIDA-funded Center for Drug Abuse Research Translation (CDART). Dr. Bardo has expertise in whole animal models and is co-PI on two NIH-funded drug discovery grants to develop selective nicotinic receptor antagonists as tobacco use cessation agents and to develop novel treatments for methamphetamine abuse.

Edward D. Hall, PhD is Director, Spinal Cord and Brain Injury Research Center and Endowed Professor of Anatomy and Neurobiology, Neurology, Neurosurgery and Physical Medicine and Rehabilitation in the College of Medicine. Following a return to academia after 20 years in the pharmaceutical industry, Dr. Hall founded Stallion Therapeutics, Inc. focused on the discovery and early development of neuroprotective pharmacological agents for acute CNS injury and other neurological care indications.

Dennie V. Jones, Jr., MD, Professor of Internal Medicine, is the Deputy Director of the Markey Cancer Center and the Interim Chief of the Division of Medical Oncology, in the College of Medicine. He is a medical oncologist with over 20 years of experience in clinical trial design and conduct, including translational phase I first-in-human trials, and drug development, including several years of clinical research in the pharmaceutical industry.

Jon S. Thorson, PhD, Professor of Pharmaceutical Sciences, Director, Center for Pharmaceutical Research and Innovation. His research interests include understanding and exploiting biosynthetic pathways and enzyme mechanisms, bioorganic and chemoselective ligation chemistries, enzyme engineering and evolution. Professor Thorson has been credited with establishing the general area of natural product glycorandomization and is a co-founder of the Madison-based biotechnology company Centrose.

David Watt, PhD is a Professor in the Department of Molecular and Cellular Biochemistry. Dr. Watt has experience in synthetic organic chemistry and new-start businesses. He serves as Director of the Organic Synthesis Core Facility, a COBRE-funded program that is part of the Center for Pharmaceutical Research and Innovation (CPRI). This Core Facility provides “small molecule” probes to an number of investigators studying interesting biological problems.

Daniel Wermeling, PharmD., FASHP, FCCP, is Associate Professor, Pharmacy Practice and Science Department, College of Pharmacy. Dr. Wermeling has been the principal investigator on over 40 Phase 1 and 2 clinical pharmacology studies and has filed 12 Investigational New Drugs.

Larry Kranking, PhD is the President and Chief Executive Officer of Coldstream Laboratories Inc. with over 40 years of experience in the Pharmaceutical & Regulated Life Sciences industry. Mr. Kranking is an internationally recognized leader who has influenced the overall regulated environment by chairing a number of collaborative teams that included both industry and FDA scientists, engineers and regulatory experts to develop the guidelines that define today's biopharma manufacturing world.

Edward Hirschowitz, MD Professor of Pulmonology, Department of Internal Medicine, College of Medicine, is a physician scientist with expertise in therapeutic vaccine development and biomarker research. Dr Hirschowitz holds the IND for five clinical studies conducted at UK using both a first and second-generation lung cancer vaccine.